MedPath

Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis

Completed
Conditions
Plaque Psoriasis
Registration Number
NCT00227240
Lead Sponsor
Pfizer
Brief Summary

The purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with Enbrel under usual care settings.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
753
Inclusion Criteria
  • Proven diagnosis of Plaque Psoriasis
Read More
Exclusion Criteria
  • Contraindications according to SmPC of Enbrel
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pfizer Investigational Site

🇩🇪

Munich, Germany

© Copyright 2025. All Rights Reserved by MedPath